Trial
NCT02573220
Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer
Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Chicago
Collaborators
National Cancer Institute (NCI)
Condition
Stage IVA Colorectal Cancer
Intervention
Cetuximab
Why stopped
Study terminated by PI due to inability to accrue.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-12-09